Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anish Thomas

Showing results (101-110 of 167) with videos related to

Pageof 17
Sort By:
Nature Communications|October 28, 2025
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped schedulingAnish Thomas, Nobuyuki Takahashi, Lenka Oplustil O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
Nature Cancer|November 21, 2022
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effectYoko Nishiga, Alexandros P Drainas, Maya Baron, et al.
Molecular Cancer Therapeutics|August 24, 2022
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP InhibitorsAnish Thomas, Shaun D Fontaine, Morgan E Diolaiti, et al.
Biorxiv : the Preprint Server for Biology|December 8, 2025
Sensitizing tumor response to topoisomerase I antibody drug conjugate by selective CDK7 inhibitionHyerim Jung, Yoonji Lee, Donghoon Yu, et al.
JAMA Network Open|February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory ArthritisAnanta Subedi, Sandra G Williams, Lawrence Yao, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancerNicole A Kirk, Jin Ng, Kate-Lin Ly, et al.
Molecular Cancer Therapeutics|May 2, 2026
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancerAzam Ghafoor, Linying Zhu, Zoe Weaver Ohler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Life (Basel, Switzerland)|August 29, 2024
Predictors of Outcomes and a Weighted Mortality Score for Moderate to Severe Subdural HematomaSima Vazquez, Aarti K Jain, Bridget Nolan, et al.
Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:
Pageof 17
Nature Communications|October 28, 2025
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped schedulingAnish Thomas, Nobuyuki Takahashi, Lenka Oplustil O'Connor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2019
Phase I/II Study of the Mesothelin-targeted Immunotoxin LMB-100 with Nab-Paclitaxel for Patients with Advanced Pancreatic AdenocarcinomaChristine Alewine, Mehwish Ahmad, Cody J Peer, et al.
Nature Cancer|November 21, 2022
Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effectYoko Nishiga, Alexandros P Drainas, Maya Baron, et al.
Molecular Cancer Therapeutics|August 24, 2022
PLX038: A Long-Acting Topoisomerase I Inhibitor With Robust Antitumor Activity in ATM-Deficient Tumors and Potent Synergy With PARP InhibitorsAnish Thomas, Shaun D Fontaine, Morgan E Diolaiti, et al.
Biorxiv : the Preprint Server for Biology|December 8, 2025
Sensitizing tumor response to topoisomerase I antibody drug conjugate by selective CDK7 inhibitionHyerim Jung, Yoonji Lee, Donghoon Yu, et al.
JAMA Network Open|February 27, 2020
Use of Magnetic Resonance Imaging to Identify Immune Checkpoint Inhibitor-Induced Inflammatory ArthritisAnanta Subedi, Sandra G Williams, Lawrence Yao, et al.
Biorxiv : the Preprint Server for Biology|October 1, 2025
SMARCA4 is essential for early-stage tumor development but its loss promotes late-stage cancer progression in small-cell lung cancerNicole A Kirk, Jin Ng, Kate-Lin Ly, et al.
Molecular Cancer Therapeutics|May 2, 2026
HDAC inhibition unlocks tumor plasticity and enhances immunotherapy response in Myc-driven small cell lung cancerAzam Ghafoor, Linying Zhu, Zoe Weaver Ohler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 4, 2018
Scientific Advances and New Frontiers in Mesothelioma TherapeuticsLuciano Mutti, Tobias Peikert, Bruce W S Robinson, et al.
Life (Basel, Switzerland)|August 29, 2024
Predictors of Outcomes and a Weighted Mortality Score for Moderate to Severe Subdural HematomaSima Vazquez, Aarti K Jain, Bridget Nolan, et al.
Pageof 17